Description

Kenvue’s Next Big Test: Can Tylenol And ZYRTEC Strength Offset Broader Weakness?

Kenvue’s second quarter of 2025 reflected ongoing challenges amid strategic transitions and shifting market dynamics. The company reported a 4.2% decline in organic sales, undershooting expectations despite underlying global consumption growth across segments. Self Care was notably impacted by unfavorable seasonal trends and customer inventory fluctuations, although 83% of the U.S. Self Care business maintained or gained market share, with flagship brands like Tylenol and ZYRTEC demonstrating strength in share and household penetration. Skin Health and Beauty showed signs of stabilization in global consumption for the first time since late 2023 but still experienced a 3.7% organic sales decline, with North America and Asia Pacific markets under pressure. Essential Health sales declined 2.4%, mainly due to volume and value contraction, with mixed regional performances. The launch of marketing campaigns like “Wash Your Mouth” for Listerine underscores efforts to reverse share declines in certain portfolios.